Europe Liquid Biopsy Market Size & Outlook, 2025-2033
The liquid biopsy market in Europe is expected to reach a projected revenue of US$ 9,997.5 million by 2033. A compound annual growth rate of 11.5% is expected of Europe liquid biopsy market from 2026 to 2033.
In terms of revenue, Europe region accounted for 30.8% of the global liquid biopsy market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 3,678.2 million by 2030.
Europe accounts for the largest revenue share of the liquid biopsy market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which can boost clinical research prospects in the region.
In Europe, high number of liquid biopsy tests have received the CE mark of approval for commercial usage. Most European countries use liquid biopsy tests as a part of cancer screening for various types of cancer, from breast cancer to lung cancer.
As a flagship action, the initiative focuses on establishing a digital infrastructure that connects resources and databases of cancer imaging data across the EU. These factors are expected to drive the market in the region.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Liquid Biopsy Market Outlook will help companies and investors design strategic landscapes.
Blood Sample Based was the largest segment with a revenue share of 80.94% in 2025.
Horizon Databook has segmented the Europe liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2021 to 2033.
Europe accounts for the largest revenue share of the liquid biopsy market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which can boost clinical research prospects in the region.
In Europe, high number of liquid biopsy tests have received the CE mark of approval for commercial usage. Most European countries use liquid biopsy tests as a part of cancer screening for various types of cancer, from breast cancer to lung cancer.
As a flagship action, the initiative focuses on establishing a digital infrastructure that connects resources and databases of cancer imaging data across the EU. These factors are expected to drive the market in the region.
Europe Liquid Biopsy Market Sample Type Outlook (Revenue, USD Million , 2021-2033)
Blood Sample Based
Others
Europe Liquid Biopsy Market Biomarker Outlook (Revenue, USD Million , 2021-2033)
Circulating Nucleic Acids
CTC
Exosomes/Microvesicles
Circulating Proteins
Europe Liquid Biopsy Market Technology Outlook (Revenue, USD Million , 2021-2033)
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Europe Liquid Biopsy Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Reproductive Health
Others
Europe Liquid Biopsy Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals and Laboratories
Specialty Clinics
Academic and Research Centers
Others
Europe Liquid Biopsy Market Clinical Application Outlook (Revenue, USD Million , 2021-2033)
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Others
Europe Liquid Biopsy Market Product Outlook (Revenue, USD Million , 2021-2033)
Instruments
Consumables Kits and Reagents
Software and Services
Reasons to subscribe to Liquid Biopsy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Liquid Biopsy Market Outlook databook
Our clientele includes a mix of Liquid Biopsy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Liquid Biopsy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Liquid Biopsy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.